Daymark Wealth Partners
VKTX icon

Daymark Wealth Partners’s Viking Therapeutics VKTX Stock Holding History

Daymark Wealth Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$292K Buy
8,959
+959
+12% +$33.2K 0.01% 703
2026
Q2 		$312K Hold
8,000
– – 0.01% 618
2026
Q1 		$260K Buy
+8,000
New +$257K 0.01% 622
2025
Q4 		– Sell
-8,000
Closed -$210K – 632
2025
Q3 		$210K Hold
8,000
– – 0.01% 582
2025
Q2 		$212K Buy
+8,000
New +$211K 0.01% 528

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Daymark Wealth Partners's VKTX Position: Q3 2026 in Review

Daymark Wealth Partners increased its Viking Therapeutics (VKTX) stake by 12% in Q3 2026, buying an estimated $33.2K and bringing the position to 8,959 shares worth $292K. The position accounts for 0.01% of the portfolio, ranked #703.

Daymark Wealth Partners first reported a position in VKTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $312K in Q2 2026. 322 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Daymark Wealth Partners held 8,959 shares of Viking Therapeutics worth $292K as of Q3 2026.
  • Daymark Wealth Partners bought 959 Viking Therapeutics shares in Q3 2026, an estimated $33.2K.
  • Viking Therapeutics made up 0.01% of Daymark Wealth Partners's portfolio in Q3 2026, its #703 holding.
  • Daymark Wealth Partners first reported a position in Viking Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Daymark Wealth Partners's Viking Therapeutics position peaked at $312K in Q2 2026.
  • 322 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Daymark Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.